Free tool
FAERS Monitor: Myobloc
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103846 or its brand name (Myobloc, Botulinum Toxin Type B). Reports on generic versions are filed under their own applications.
Reports
328
Serious
188
57% of reports
Hospitalization
65
Death reported
58
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dry mouth46
- dysphagia43
- death42
- product use in unapproved indication34
- drug ineffective30
- headache23
- vision blurred22
- off label use21
- dyspnoea15
- constipation14
- nausea14
- neck pain14
- pain14
- asthenia13
- fatigue12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 37 |
| 2005 | 5 |
| 2006 | 13 |
| 2007 | 11 |
| 2008 | 8 |
| 2009 | 7 |
| 2010 | 5 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 7 |
| 2016 | 6 |
| 2017 | 16 |
| 2018 | 20 |
| 2019 | 15 |
| 2020 | 16 |
| 2021 | 23 |
| 2022 | 28 |
| 2023 | 24 |
| 2024 | 29 |
| 2025 | 32 |
| 2026 | 15 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,831 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dry mouthSignal | 46 | 36.4 | 27.8 | 1,552 |
| dysphagiaSignal | 43 | 29.1 | 22.0 | 1,142 |
| neck painSignal | 14 | 16.1 | 9.6 | 183 |
| vision blurredSignal | 22 | 10.3 | 6.9 | 176 |
| product use in unapproved indicationSignal | 34 | 8.8 | 6.4 | 230 |
| constipationSignal | 14 | 4.1 | 2.5 | 30 |
| deathSignal | 42 | 3.1 | 2.4 | 61 |
| headacheSignal | 23 | 2.4 | 1.6 | 17 |
| astheniaSignal | 13 | 2.2 | 1.3 | 8 |
| dyspnoea | 15 | 1.7 | 1.0 | 4 |
| off label use | 21 | 1.5 | 1.0 | 4 |
| pain | 14 | 1.5 | 0.9 | 2 |
| drug ineffective | 30 | 1.5 | 1.0 | 4 |
| nausea | 14 | 1.1 | 0.7 | 0 |
| fatigue | 12 | 1.0 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.